Resource impact statement
No significant resource impact is anticipated
We do not expect this updated guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is a further treatment option and the overall incremental resource impact of treatment is low.
Cladribine is less costly and needs less frequent dosing and monitoring than some of the other treatment options. However, any savings as a result of implementing the updated recommendations are not expected to be significant at a national level.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: